MINERVA NEUROSCIENCES INC (NERV) Stock Price & Overview
NASDAQ:NERV • US6033802058
Current stock price
The current stock price of NERV is 5.23 USD. Today NERV is down by -0.95%. In the past month the price decreased by -12.98%. In the past year, price increased by 260.69%.
NERV Key Statistics
- Market Cap
- 226.302M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.32
- Dividend Yield
- N/A
NERV Stock Performance
NERV Stock Chart
NERV Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NERV. When comparing the yearly performance of all stocks, NERV is one of the better performing stocks in the market, outperforming 97.59% of all stocks.
NERV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NERV. While NERV seems to be doing ok healthwise, there are quite some concerns on its profitability.
NERV Earnings
NERV Forecast & Estimates
7 analysts have analysed NERV and the average price target is 7.4 USD. This implies a price increase of 41.4% is expected in the next year compared to the current price of 5.23.
NERV Groups
Sector & Classification
NERV Financial Highlights
Over the last trailing twelve months NERV reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS increased by 31.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -299.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NERV Ownership
NERV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 365.463B | ||
| AMGN | AMGEN INC | 15.01 | 184.669B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 43.81B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.036B | ||
| BIIB | BIOGEN INC | 10.72 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.261B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.39 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NERV
Company Profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Company Info
IPO: 2014-06-25
MINERVA NEUROSCIENCES INC
1601 Trapelo Road, Suite 284
Waltham MASSACHUSETTS 02451 US
CEO: Remy Luthringer
Employees: 7
Phone: 16176007373
MINERVA NEUROSCIENCES INC / NERV FAQ
Can you describe the business of MINERVA NEUROSCIENCES INC?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
What is the stock price of MINERVA NEUROSCIENCES INC today?
The current stock price of NERV is 5.23 USD. The price decreased by -0.95% in the last trading session.
Does NERV stock pay dividends?
NERV does not pay a dividend.
How is the ChartMill rating for MINERVA NEUROSCIENCES INC?
NERV has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the ex-dividend date for NERV stock?
The next ex-dividend date for MINERVA NEUROSCIENCES INC (NERV) is November 3, 2022.
Can you provide the market cap for MINERVA NEUROSCIENCES INC?
MINERVA NEUROSCIENCES INC (NERV) has a market capitalization of 226.30M USD. This makes NERV a Micro Cap stock.
What is the next earnings date for NERV stock?
MINERVA NEUROSCIENCES INC (NERV) will report earnings on 2026-05-11.